
The Best Red-Light Therapy Device
Connie Park/NYT Wirecutter
Connie Park/NYT Wirecutter
Connie Park/NYT Wirecutter
At first blush, the LightStim for Wrinkles seems devoid of bells and whistles. But it dazzles where it truly matters: in the jam-packedness of its 72 LEDs, its handiness, and its foolproof one-button operating system. Like all wands, though, it requires you to actively engage with it, and it's not cordless.
For a handheld device, it's loaded with LEDs. If you're going to put in the time and effort to manually move a wand around, it should cover a good portion of your face. And the LightStim does just that, with 72 LEDs packed into a circle that's just a skosh under 5 square inches. In comparison, the Lumicure Light Therapy Torch has three LEDs in a 0.78-square-inch circle, and while the Solwave 4-in-1's little 0.75-square-inch wand head has 14 (seven dual) LEDs, it requires significantly more elbow grease to equally treat the same amount of skin. Some testers liked that they could simply press the LightStim's large head against their faces until the three-minute timer signaled that they could move it to a different location.
This wand emits four different wavelengths of red light. The wavelength is what determines light's color, and these LEDs are amber (605-nanometer wavelength), light red (630 nm), deep red (680 nm), and near infrared (855 nm). The varying wavelengths spark different reactions at various levels of the skin: Amber, red, and infrared penetrate to reduce oil and inflammation, as well as to stimulate collagen and elastin production, which makes skin look plumper and firmer and minimizes the appearance of fine lines. (Since infrared is invisible, the 865 nm LEDs might not appear lit, even when the power is on.) The Solawave 4-in-1, meanwhile, emits a single wavelength, 630 nm. One tester loved the LightStim's range of reds, especially for treating nasolabial folds and other lines around her mouth.
The simple design makes it beyond easy to use, and silent. The LightStim is on or off — and that's all there is to it. Every three minutes, a quick tone indicates that it's time for you to move it to a different part of your face or body (unlike most of the devices we tested, this wand has no automatic shutoff). Whereas the Solawave 4-in-1 buzzes and lightly vibrates, the LightStim is dead quiet and inert in the palm, with one tester likening it in vibes and looks to an old-timey candlestick telephone. Testers also appreciated that the wand's single button required zero practice or guesswork. You also operate the Therabody TheraFace and Dr. Dennis Gross DRx Spectralite via on-device push buttons, but those models, both of which are masks, require cycling through many presses to change modes, and while the mask is attached to your face, it's hard to tell which color mode you're in.
You can use it on other body parts. Signs of aging aren't limited to the face, and our testers liked using the LightStim on their necks, décolletages, and even scars, as well. Sure, our flexible mask pick, the Omnilux Men, can also be placed on or wrapped around body parts other than the face, but the LightStim was the easiest device to use in this regard.
Flaws but not dealbreakers
The LightStim can drag a bit against skin unless you use it with a serum. But this was true of all the wands we tried. Our testers found it more comfortable to press the wand head against the skin and hold it there for a bit.
It needs to be plugged in. Of the 11 devices we tested, the LightStim is the only one that has a cord. For something you use for about 12 minutes at a time, staying within 6 feet of an outlet isn't such a big deal, and the wand will never conk out mid-treatment (as the rechargeable Solawave 4-in-1 did a few times in our tests). Complicating matters, though, is that the AC/DC adapter detaches from the wand — increasing its chances of being misplaced.
The plastic housing feels a bit cheap. Especially when you consider the wand's $250 price tag.
Key specs
LEDs: 72
Wavelengths: 605 nm, 630 nm, 660 nm, 865 nm
Irradiance: 65 mW/cm2
Treatment time: three minutes per area (no automatic shutoff)
Charging: none; powered by AC/DC adapter
Return policy: 30 days when bought from LightStim
Warranty: five years

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberg will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 10:30 am ET and will be webcast simultaneously. Sophisticated imaging and radiological tools are increasingly enabling medicines developers to leverage biomarkers earlier in clinical development to identify signals of biological target engagement and pharmacodynamic activity. Discussion will focus on how these tools drive evidence informed approaches in drug development and provide insight into potential clinical outcomes. Ovid management will describe the exploratory biomarkers in use to measure its next-generation GABA-aminotransferase (GABA-AT) inhibitor program, OV329, which is anticipated to have a topline readout in Q3 2025. Keynote speaker: Leading pediatric neurologist and epileptologist Alexander Rotenberg, M.D., Ph.D. Professor of Neurology at Boston Children's Hospital and Harvard Medical School, and Director of the Epilepsy Monitoring Unit at Boston Children's Hospital, and the Experimental Neurophysiology Core at F.M. Kirby Center of Neurobiology Unfortunately, nearly 40 percent of people living with epilepsy continue to experience seizures despite existing medicines. OV329 is a next-generation GABA-AT inhibitor, that was rationally designed to work differently from current medicines and may offer a novel approach for patients with treatment-resistant seizures. OV329 seeks to endogenously deliver optimal levels of GABA to reduce seizures and provide a preferable safety and tolerability profile relative to the first-generation, GABA-AT inhibitor, vigabatrin. OV329 is currently completing a Phase 1 study that is evaluating its effects on multiple pharmacodynamic biomarkers, safety, tolerability, and pharmacokinetics. Interested in attending or participating remotely: To register, please visit: Registration Link A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit Forward-Looking Statements This press release includes certain disclosures by Ovid that contain 'forward-looking statements' including, without limitation: statements regarding the expected timing of initiation, completion, and results and data of Ovid's clinical studies; the potential use and development of OV329, OV350, OV4071 and other compounds from Ovid's library of direct activators of KCC2; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'may,' 'plan,' 'potentially,' and 'will,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its business strategy or unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption 'Risk Factors' in Ovid's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ('SEC'), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Media and Investor Relations:Victoria Fort vfort@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


News24
an hour ago
- News24
Joshua Jackson in custody battle with his ex-wife over daughter's schooling
The ink has barely dried on Joshua Jackson and Jodie Turner-Smith's divorce papers, and already the exes are locked in a bitter legal dispute over their shared parenting arrangement. The Doctor Odyssey star has filed an emergency custody review, claiming his ex-wife enrolled their five-year-old daughter, Juno, in a new school without his consent. In the documents, obtained by People magazine, Joshua (46) alleges that Jodie (38) believes, 'it's no big deal to force Juno to start over with a new school'. He also complains that the new school is 45 minutes away from his home, making regular drop-offs and pick-ups nearly impossible for him. However, Joshua's concern goes beyond the school change itself. 'Jodie is attempting to create a scenario where Juno travels with her rather than attending a traditional school,' he claims. The Dawson's Creek star wants the court to order that their daughter remains in her current school in Calabasas, in Los Angeles, for the upcoming academic year. He also wants it stipulated that both parents must agree before any future school changes can be made. View this post on Instagram A post shared by THE AGENCY: CENTRAL INTELLIGENCE (@theagency_sho) Joshua and Jodie met at a 2018 party hosted by R&B singer Usher. They married in secret a year later before welcoming Juno in April 2020. In October 2023, the British model and actress filed for divorce on the grounds of 'irreconcilable differences'. Joshua recently told USA Today that he believes Jodie is attempting to change their daughter's schooling so there is more flexibility for Juno to accompany her when she needs to travel for work. READ MORE| 'I don't think of it as a failure' – Jodie Turner-Smith on divorcing Joshua Jackson He says he thinks maintaining educational stability is important for their daughter's well-being during her formative years – something he didn't experience as a child actor. 'I started acting at a young age. I have spent a lot of time with on-set or on-location tutors,' he said. 'Even in the best case, it cannot begin to provide a child with the same nurturing and enrichment, peer relationships and social skills that a classroom and school community environment provides.' He added that Juno has already endured a lot of changes, from their divorce to her home burning down during the LA wildfires in January, so she doesn't need any more turmoil. 'Unnecessary school change cannot be in her interests.' Jodie is yet to speak publicly on the matter. Despite their legal woes, it seems they're both moving on with their lives. View this post on Instagram A post shared by Joshua Jackson (@vancityjax) Jodie currently stars in The Agency as Dr Sami Zahir, an academic who becomes romantically involved with an undercover CIA agent. Describing her role she says, 'I love playing a dark-skinned Sudanese woman speaking Arabic on this show. I believe it's one of the most beautiful languages on this planet and I hope that Arabic-speaking people feel represented.' She is also set to be filming in London throughout next year. Meanwhile, Joshua is gearing up to return to his home in LA, which had to be rebuilt after being destroyed in the wildfires.
Yahoo
an hour ago
- Yahoo
2 Recession-Proof Stocks to Buy and Hold
Even amid an uncertain economic environment, reliable companies can be found. Zoetis helps people care for pets, which many consider as honorary family members. HCA Healthcare offers services in high demand, regardless of economic conditions. 10 stocks we like better than Zoetis › President Trump's trade policies are sparking concerns about a potential recession. Though it's hard to predict an upcoming economic downturn, it's never a bad idea for investors to buy shares of companies that can perform relatively well even in bad times. These corporations often have robust underlying businesses built to deliver consistent results and superior returns over the long run. Here are two great examples for investors to consider: Zoetis (NYSE: ZTS) and HCA Healthcare (NYSE: HCA). Zoetis, a leading animal health company, has faced some challenges over the past year. The company's recent financial results weren't great, and it is dealing with increased competition for some of its growth drivers, including Apoquel, a medicine to treat allergic itch in dogs. However, as Zoetis points out, there is significant whitespace in this niche. It estimates that 13 million dogs are eligible for the medicine but aren't on any prescription, and another 7 million are undertreated. The company currently treats 12 million dogs with Apoquel and Cytopoint, a similar medicine. Although Zoetis markets products for livestock, poultry, and other animals, the company's work with pets, particularly cats and dogs, is one of the primary reasons it can survive a recession relatively unscathed. People view their pets as family members and are more than willing to pay a significant amount to ensure they are well cared for. The increased humanization of pets should also be a significant long-term growth driver for Zoetis, a trend that is particularly prevalent among younger generations, who are less likely to have children than older ones. It might be pushing it to say that pets are the new kids, but it's not too far from the truth for many pet owners. The rest of Zoetis' business grants it significant diversity. The animal health leader generally grows its revenue at rates faster than the industry average, something it has been able to do for a while, despite competition, through the continuous development of newer medicines. Two of its more recent important approvals, Solensia and Librela that treat osteoarthritis pain in cats and dogs, respectively, are becoming key growth drivers, too. So, despite being slightly in the red over the trailing-12-month period, Zoetis is well-equipped to handle a recession if one is coming, while delivering strong returns in the long run. Lastly, the stock is also an excellent pick for income seekers despite its unimpressive forward yield of 1.2%. Zoetis has increased its payouts by 502% in the past decade. Whether it's for dividends or growth, the healthcare specialist is a great option. HCA Healthcare's business remains in high demand even in recessions. The company is a leading hospital chain in the U.S., and even during economic downturns, people still require critical medical care. True, some procedures performed in the company's facilities are optional. Even for those that aren't, patients may sometimes postpone them when things get tough. So, there will be an impact on the company's results, but it should be fairly minimal. Over the past year, the company has faced another source of headwinds. Various natural disasters, including hurricanes, impacted its financial results in some areas, resulting in lower revenue than anticipated. Still, HCA Healthcare continues to deliver decent updates. In the first quarter, the company's revenue increased by a modest 5.7% year over year to $18.3 billion. Its earnings per share came in at $6.45, up 8.8% compared to the year-ago period. Despite this headwind, HCA Healthcare's long-term prospects are attractive. An aging population that will require more medical care should lead to increased spending on precisely the kinds of services it offers. HCA Healthcare has also deepened its relationships with physicians, patients, and third-party payers over time, partly through the adoption of more services. It would be challenging for any newcomer to seriously challenge HCA Healthcare, considering the ecosystem it has already built, which arguably grants it a network effect. Although there is competition, HCA Healthcare has generally increased its market share over the past decade. The stock should continue delivering superior returns long after the next recession hits, whenever that happens. Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Zoetis. The Motley Fool recommends HCA Healthcare. The Motley Fool has a disclosure policy. 2 Recession-Proof Stocks to Buy and Hold was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data